Lelia B.
- Country
- Germany
- Department
- Fachabteilung für Gynäkologie und Geburtshilfe
Research Overview
- Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab versus Chemotherapy in Clinical Stage II-III Triple-Negative Early Breast Cancer
- CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
- Phase III Randomized, Double-Blind Trial of Atezolizumab with Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients
Data & Insights
Has run more than one trial at 144 of 372 partner sites.
Specializations
Breast Cancer Therapeutics
This investigator specializes in developing innovative treatments for early-stage breast cancer, with particular emphasis on hormone receptor-positive (HR+) and HER2-negative breast cancer subtypes.
- Triple-negative breast cancer management
- Hormone receptor-positive therapy approaches
- Early-stage breast cancer interventions
The investigator focuses on evaluating novel therapeutic combinations including targeted therapies and immunotherapy approaches.
Personalized Medicine
The investigator advances dynamic marker-adjusted personalized therapy approaches, tailoring treatments based on individual patient characteristics and disease markers.
- Biomarker-driven treatment selection
- Risk-stratified therapeutic approaches
- Adaptive treatment strategies
Their work encompasses the development of personalized endocrine therapy combinations for specific patient populations.
Clinical Outcomes Research
The investigator studies disease-free survival outcomes and evaluates therapeutic effectiveness in various breast cancer treatment approaches.
- Long-term survival analysis
- Treatment response assessment
- Comparative effectiveness research
Their research includes evaluation of both adjuvant therapy strategies and neoadjuvant treatment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.